Viridian Therapeutics 3Q 2026: Revenue $25.8M, Net loss $101.2M, EPS $(0.81) — 10-Q Summary
Viridian Therapeutics reported 3Q 2026 revenue of $25.8M, a net loss of $101.2M, and EPS of $(0.81). This compares to $70.6M revenue and a $34.6M net loss in the prior-year quarter. The company's newly launched drug, veligrotug, generated $24.7M in U.S. sales. Viridian also announced positive Phase 3 trial results for elegrobart and plans for upcoming trials.
How this was made

The 30-second read
Why it matters
The Q3 2026 earnings release provides the first public numbers for the post‑approval quarter, setting a baseline for future performance.
Market read
The report offers fresh data on a micro‑cap biotech, combining a loss with a regulatory win, which may affect short‑term trading and longer‑term valuation.
What to watch
Potential future revenue from upcoming trial readouts and the upcoming BLA filing in Q1 2027.
Background
Viridian Therapeutics (VRDN) is a clinical‑stage biotech focused on rare endocrine disorders. The company recently received FDA approval for its veligrotug product, Lumvoa.
Ticker impact
Viridian Therapeutics filed its 10‑Q reporting Q3 2026 results, including $25.8M revenue, $101.2M net loss and FDA approval of Lumvoa.
likely pressure as the market prices in the larger-than-expected loss, offset partially by the FDA approval and new product revenue.
Quarterly results are the first public disclosure of these numbers; the loss magnitude is material for a micro‑cap, and FDA approval is a significant catalyst.
Market effects
Highlights progress in the biotech/rare‑disease space and may influence peer valuations.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
Despite the loss, the FDA approval and early sales could drive a short‑term rally if investors focus on the upside.
Key entities
- companyViridian Therapeutics
Biotech firm reporting Q3 2026 results and FDA approval.
- regulatorFDA
Approved Lumvoa for commercial use.
